Sarbajit Mukherjee, MD, MS Sarbajit Mukherjee, MD, MS

Sarbajit Mukherjee

Medical Oncology

Specializing In:

Esophageal Cancer Gastric Cancer Neuroendocrine Tumors Colon Cancer

Special Interests:

Use of immune checkpoint inhibitors in solid tumors

About Sarbajit Mukherjee


Oncology is one of the most academic disciplines of medicine, and its scientific concepts are rapidly evolving. Over the past few years, a convergence of innovations has created an unprecedented opportunity for us to make a big impact on cancer. Working at a top-notch institution like Roswell Park Comprehensive Cancer Center allows me to integrate those cutting age innovations into the day-to-day care of my patients. I hope to see a day when cancer, stripped of its intimidation, will be "a word, not a sentence."


Roswell Park Comprehensive Cancer
  • Assistant Professor of Oncology
  • Department of Medicine
Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
  • Clinical Assistant Professor


Education and Training:

  • 2010 - MD - Nilratan Sircar Medical College, West Bengal University of Health Sciences, India
  • 2018 - MS - Master of Science in Clinical and Translational Science, University of Oklahoma, Oklahoma City, OK


  • 2012-2015 - Saint Joseph Hospital, Chicago, IL


  • 2015-2018 - University of Oklahoma Health Sciences Center, Oklahoma City, OK

Board Certification:

  • 2018 - Medical Oncology - American Board of Internal Medicine
  • 2018 - Hematology - American Board of Internal Medicine
  • 2015 - Internal Medicine - American Board of Internal Medicine

Professional Memberships:

  • Esophageal Cancer Action Network - Board of Directors

Professional Experience:

  • 2017-2018 - Clinical Practice Guidelines Committee, ASCO
  • 2017-2018 - Chief fellow, Hematology-Oncology, University of Oklahoma
  • 2016-2018 - Professional Development Committee, ASCO

Clinical Trials


Full Publications list on PubMed
  1. Gosain R, Anwar S, Miller A, Iyer R, Mukherjee S. Interleukin-6 as a biomarker in patients with hepatobiliary cancers. J Gastrointest Oncol. 2019 Jun;10(3):537-545. PubMed PMID: 31183205
  2. Wang Z, Aguilar EG, Luna JI, Dunai C, Khuat LT, Le CT, Mirsoian A, Minnar CM, Stoffel KM, Sturgill IR, Grossenbacher SK, Withers SS, Rebhun RB, Hartigan-O'Connor DJ, Méndez-Lagares G, Tarantal AF, Isseroff RR, Griffith TS, Schalper KA, Merleev A, Saha A, Maverakis E, Kelly K, Aljumaily R, Ibrahimi S, Mukherjee S, Machiorlatti M, Vesely SK, Longo DL, Blazar BR, Canter RJ, Murphy WJ, Monjazeb AM. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med. 2019 Jan; 25(1):141-151. PubMed PMID: 30420753.
  3. Huang H, Salavaggione O, Rivera L, Mukherjee S, Brekken R, Tennant B, Iyer R, Adjei A. Woodchuck VEGF (wVEGF) characteristics: Model for angiogenesis and human hepatocellular carcinoma directed therapies. Arch Biochem Biophys. 2019 Jan; 661:97-106. PubMed PMID: 30439360.
  4. Samuel S, Mukherjee S, Ammannagari N, Pokuri VK, Kuvshinoff B, Groman A, LeVea CM, Iyer R. Clinicopathological characteristics and outcomes of rare histologic subtypes of gallbladder cancer over two decades: A population-based study. PLoS One. 2018 Jun 11; 13(6):e0198809. PubMed PMID: 29889907.
  5. Mukherjee S, Ibrahimi S, Khalid B, Roman D, Zhao D, Aljumaily R. Do proton pump inhibitors modulate the efficacy of anti-PD-1/PD-L1 therapy? A retrospective study. J Oncol Pharm Pract. 2018 Jan 1:1078155218771152. PubMed PMID: 29690815.

Request an Appointment

Make an appointment by calling 1-800-ROSWELL (1-800-767-9355)

Make an Appointment